Bibliographic record
Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a…
Del Prato S, Kahn SE, Pavo I, Weerakkody GJ, Yang Z, Doupis J, Aizenberg D, Wynne AG, Riesmeyer JS, Heine RJ, Wiese RJ. The Lancet 2021
§1Bibliographic record
§1.1Record
- Authors
- Del Prato S, Kahn SE, Pavo I, Weerakkody GJ, Yang Z, Doupis J, Aizenberg D, Wynne AG, Riesmeyer JS, Heine RJ, Wiese RJ
- Title
- Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial
- Source
- The Lancet
- Year
- 2021
- Volume, issue, pages
- 398(10313):1811–1824
- Digital object identifier
- 10.1016/S0140-6736(21)02188-7
- PubMed identifier
- 34672967
- Record type
- Journal article
- Institute identifier
- CEI-BR-015
§1.2Institute documents citing this record
Table 1. Documents in the Institute set that cite this record.
| Document | Series |
|---|---|
| Monograph: Tirzepatide | Compound monograph |
| 1 citing document. | |
§1.3Subject tags
tirzepatide insulin SURPASS
Compound Evidence Institute · CEI-BR-015 · https://compoundevidence.com/bibliography/delprato2021/ · retrieved 30 July 2026